Attached files
| file | filename |
|---|---|
| EX-99.3 - MyMD Pharmaceuticals, Inc. | ex99-3.htm |
| EX-99.2 - MyMD Pharmaceuticals, Inc. | ex99-2.htm |
| EX-99.1 - MyMD Pharmaceuticals, Inc. | ex99-1.htm |
| EX-32.2 - MyMD Pharmaceuticals, Inc. | ex32-2.htm |
| EX-32.1 - MyMD Pharmaceuticals, Inc. | ex32-1.htm |
| EX-31.2 - MyMD Pharmaceuticals, Inc. | ex31-2.htm |
| EX-31.1 - MyMD Pharmaceuticals, Inc. | ex31-1.htm |
| EX-10.19 - MyMD Pharmaceuticals, Inc. | ex10-19.htm |
| EX-10.17 - MyMD Pharmaceuticals, Inc. | ex10-17.htm |
| EX-10.16 - MyMD Pharmaceuticals, Inc. | ex10-16.htm |
| EX-10.15 - MyMD Pharmaceuticals, Inc. | ex10-15.htm |
| EX-10.14 - MyMD Pharmaceuticals, Inc. | ex10-14.htm |
| EX-10.13 - MyMD Pharmaceuticals, Inc. | ex10-13.htm |
| EX-10.12 - MyMD Pharmaceuticals, Inc. | ex10-12.htm |
| EX-10.11 - MyMD Pharmaceuticals, Inc. | ex10-11.htm |
| EX-10.10 - MyMD Pharmaceuticals, Inc. | ex10-10.htm |
| EX-10.9 - MyMD Pharmaceuticals, Inc. | ex10-9.htm |
| EX-10.8 - MyMD Pharmaceuticals, Inc. | ex10-8.htm |
| EX-10.3 - MyMD Pharmaceuticals, Inc. | ex10-3.htm |
| 10-Q - MyMD Pharmaceuticals, Inc. | form10-q.htm |
Exhibit 10.18
First Amendment to Employment Agreement
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Paul M. Rivard, Esq. (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated September 21, 2020 (“Agreement”); and
WHEREAS, for good and valuable consideration the Parties hereby wish to amend the Agreement as follows:
Exhibit “C” to the Agreement is replaced with the Exhibit “C” appended hereto.
| MYMD Pharmaceuticals, Inc. | |
| /s/ James A. McNulty | |
| By: James A. McNulty, CEO | |
| Paul M. Rivard, Esq. | |
| /s/ Paul M. Rivard, Esq. |
| 1 |
EXHIBIT “C”
Milestone Bonuses due upon achievement of milestones
Set forth below is the schedule pursuant to which the Employee will be paid $20,000 at the time each of the pending patent applications are issued to the Company. Each bonus will be paid 30 days after receipt of the Issued Patent.
| Title | Assignee | App. No. | Estimated (Actual) Issuance | |||
| Methods of Reversing Normal Aging Process and Extending Lifespan | MyMD Pharmaceuticals, Inc. | 16/680,677 | 2Q 2021 | |||
| Pharmaceutical Salts of Isomyosmine and Pharmaceutical Compositions Containing Same | MyMD Pharmaceuticals, Inc. | 16/672,714 | (10/20/2020) | |||
| Method of Regulating Tumor Necrosis Factor-alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation | MyMD Pharmaceuticals, Inc. | 16/785,747 | (11/17/2020) | |||
| Method of Treating Viral Infections | MyMD Pharmaceuticals, Inc. | 16/791,290 | (9/29/2020) | |||
| Method of Treating Coronavirus | MyMD Pharmaceuticals, Inc. | 16/792,492 | 1Q 2021 | |||
| Methods of Regulating Oxidoreductase for Treatment of Aging and Age-related Disorders | MyMD Pharmaceuticals, Inc. | 16/928,255 | 4Q 2021 | |||
| Method of Treating Disorders Associated with Chronic Inflammation | MyMD Pharmaceuticals, Inc. | 17/084,012 | 1Q 2022 | |||
| Synthetic Cannabinoid Compounds for Treatment of Substance Addiction and Other Disorders | Supera Pharmaceuticals, Inc. | 16/612,472 | 1Q 2021 |
| 2 |